Importantly, these experimental platforms have an opportunity to create real world impact in light of the US Food and Drug Administration policy allowing certain in vitro methodologies to be used to indicate CFTR modulator treatments for the clinical treatment of people bearing specific CF variants (87). Here, CFTR is linked to cystic fibrosis.